Advancing a Pipeline of ERM Therapies
Oxia is developing a pipeline of Endogenous Repair Modulators designed to activate the body’s own mechanisms for protection, repair, and restoration. Our approach precisely targets epigenetic programs that activate cellular healing across multiple organs, enabling therapies that are not limited by disease type but guided by biology. Each candidate in our pipeline is built to deliver meaningful patient impact by precisely activating programs that protect tissues, amplify wound healing, and revitalize healthy cellular function.
Lead Indication: Stroke
U.S. 800K new cases per year
Lead Indication: Renal Failure
U.S. 35M living with chronic kidney disease
Myocardial Infarction & Heart Failure
U.S. 6.5M living with heart failure
Our Therapeutic Approach
Oxia is advancing a pipeline of ERM therapies that aim to solve long-standing gaps in care across multiple indications. Our delivery formats will be built for accessibility, allowing use anywhere for acute injury or illness and long-term treatment for chronic disease.
Intravenous (IV)
High bioavailability for hospital-based, severe injury or emergency care
Oral Tablets
Convenient systemic option for chronic and degenerative conditions
Nasal Spray
Rapid-acting, non-invasive option for acute CNS and trauma indications
Topical
Localized treatment for wounds, burns, and inflammatory skin conditions
Strong Patent Portfolio
Oxia’s lead compound is protected by a composition of matter patent and supported by a growing portfolio of platform and molecule innovations. Our intellectual property strategy provides broad global protection for our Endogenous Repair Modulators, including both stimulators and inhibitors across multiple therapeutic areas.
Oxia’s IP estate spans multiple families and continuations, with region-specific grants and allowances, indicating resilient claim sets. These patent families create a strong, multilayered foundation that protects our chemistry, our mechanism, and our approach to activating intrinsic repair. This portfolio gives Oxia a diversified set of opportunities and a uniquely differentiated pathway for advancing next-generation SRC-targeted medicines.
SRC Stimulator Family #1
Cardiovascular Indications
SRC Stimulator Family #2
Non-CV, Non-Oncology Indications
SRC Inhibitor Family
Emerging Programs
FDA Regulatory Pathway for Human Clinical Trials
Oxia is laying the groundwork for a clear and efficient regulatory path toward human clinical trials. As we advance our lead ERM compound through discovery and preclinical validation, we are aligning our scientific strategy with FDA expectations to ensure a smooth transition into IND-enabling studies. We anticipate initiating human clinical trials in early 2027.
Product
Endogenous Repair Modulators
Indication
Stroke
Renal Failure
Myocardial Infarction & Heart Failure
Discovery
Pre-Clinical
Studies
IND-enabling
Clinical Trial
Oxia’s ERM therapies target stroke, kidney injury, MI, fibrosis and more — reprogramming repair biology from within.
Stroke
Protect brain tissue and accelerate recovery
Heart Attack
Help the heart rebuild after injury
Kidney Injury
Preserve function and prevent scarring
Fibrosis & Trauma
Reverse scarring and restore tissue
Our modular platform is developed for multiple delivery routes — IV, oral, nasal, and topical — bridging acute care and long-term regeneration.
Oxia’s ERM therapies target stroke, kidney injury, MI, fibrosis and more — reprogramming repair biology from within.
12M
new strokes annually worldwide
6.5M
stroke-related deaths each year
35M
Americans living with chronic kidney disease
800K
Patients in the U.S. living with end-stage renal disease (ESRD)
Key Takeaways
Oxia is advancing scientific discoveries into a new class of medicine: Endogenous Repair Modulators (ERM)
Targets a core regenerative pathway involved in complex tissue repair.
Enhances healing across a wide range of injury types by activating a shared biological mechanism.
In cellular stress environments, our platform switches on innate repair programs that restore tissue and cellular function.
Features a straightforward and scalable synthetic pathway.
Strong IP packet that extends from composition of matter, method of treatment, to formulation.
We are driven by a purpose to change how the world heals, helping people not just survive disease but truly recover and thrive.
Our modular platform is developed for multiple delivery routes — IV, oral, nasal, and topical — bridging acute care and long-term regeneration.
Lorem Ipsum
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
